`Inexact Substitutes'

Frederick Goodwin and Adrian Morrison misinterpreted my statements regarding animal experimentation in their commentary of Sept. 6, 1993 ("In Animal Rights Debate, The Only Valid Moderates Are Researchers," page 12). The point I made was that medical research is based primarily on studies of human individuals or populations, along with examination of human tissues and cells. Those who use animals as inexact substitutes always encounter problems of extrapolation to humans, often with grave con

Written byNeal Barnard
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

Those who use animals as inexact substitutes always encounter problems of extrapolation to humans, often with grave consequences. The deaths of five human subjects following "successful" tests of a hepatitis drug on dogs is the latest example. Overall, of 198 drugs marketed during the decade 1976- 85, more than half (102) were so much more toxic than premarket animal and limited human trials had indicated that they had to be relabeled or withdrawn.

Similarly, of 25 drugs that appeared to treat strokes in rodents, not a single one worked in people. Millions of dollars, years of effort, and hundreds of animals were lost for nothing.

It is time to stop cheerleading for this expensive and gruesome activity and to start rolling up our sleeves to replace animal experiments with nonanimal models.

NEAL D. BARNARD
President, Physicians Committee for Responsible Medicine
Washington, D.C.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies